WAVE.V · Waverley Pharma Inc

-

Please sign in to comment on WAVE.V

1 Comment

Admin

4 years ago

Waverley Pharma Inc is currently in a long term downtrend where the price is trading 20.0% below its 200 day moving average.

From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.

Waverley Pharma Inc's total revenue rose by 33.7% to $353K since the same quarter in the previous year.

Its net income has increased by 100.2% to $989 since the same quarter in the previous year.

Finally, its free cash flow grew by 129.3% to $179K since the same quarter in the previous year.

Based on the above factors, Waverley Pharma Inc gets an overall score of 4/5.

CurrencyCode	CAD
Sector	Healthcare
Industry	Biotechnology
Exchange	V
ISIN	CA94357L1058

Beta	1.85
Market Cap	540K
PE Ratio	None
Target Price	10
Dividend Yield	None

ABOUT

Waverley Pharma Inc

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. It also focuses on generic oncology injectable products. The company offers generic oncology products, such as temozolomide, capecitabine, and erlotinib. It also provides injectable generic chemotherapy drugs, such as pemetrexed for the treatment of non-small cell lung cancer and other indications; and bortezomib to treat multiple myeloma and other indications. In addition, the company develops PARP-1 inhibitors for cancer treatment. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

WAVE.V · Waverley Pharma Inc

-

Waverley Pharma Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Waverley Pharma Inc using a moving average strategy